Grapefruit juice-drug interaction and the prediction

葡萄柚汁与药物的相互作用及预测

基本信息

  • 批准号:
    12557225
  • 负责人:
  • 金额:
    $ 8.45万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 财政年份:
    2000
  • 资助国家:
    日本
  • 起止时间:
    2000 至 2001
  • 项目状态:
    已结题

项目摘要

Grapefruit-drug interaction was investigated to understand the mechanism and influence on drug therapy. We first identified the causative chemicals in grapefruit juice as furanocoumarin-geranylderivatives including GF-I-1 and GF-I-4. These chemicals were found to be strong inhibitors of a human cytochrome P450, CYP3A4. We showed that less than 50 ml intake of the juice altered the kinetic profile of midazolam, which was metabolized by CYP3A4. Selective influence of the juice on intestinal CYP3A4 was shown with volunteers taking omeprazole. Furanocoumarins were shown to decrease intestinal CYP3A4 by both competitive and inactivation, possibly through intermediate complex formation. In addition, we found that grapefruit intake suppress DNA lesion induced by dietary carcinogen PhIP. We are currently investigating the chemoprevention mechanism. To assess the influence of the juice component on CYP3A4 induction, we are developing the in vitro assay system of CYP3A4 gene activation. We have a plan to test the furanocoumarins for the inducibility of CYP3A4.
研究葡萄柚-药物相互作用以了解其机制和对药物治疗的影响。我们首先确定了葡萄柚汁中的致病化学物质为呋喃香豆素-香叶基衍生物,包括GF-I-1和GF-I-4。这些化学物质被发现是人类细胞色素P450,CYP 3A 4的强抑制剂。我们发现,少于50毫升的果汁摄入量改变了咪达唑仑的动力学特征,咪达唑仑是由CYP 3A 4代谢的。服用奥美拉唑的志愿者显示果汁对肠道CYP 3A 4的选择性影响。呋喃香豆素类通过竞争性和失活降低肠道CYP 3A 4,可能是通过中间复合物的形成。此外,我们发现葡萄柚摄入量抑制膳食致癌物PhIP诱导的DNA损伤。我们目前正在研究化学预防机制。为了评估果汁成分对CYP 3A 4诱导的影响,我们正在开发CYP 3A 4基因激活的体外测定系统。我们计划测试呋喃香豆素对CYP 3A 4的诱导作用。

项目成果

期刊论文数量(38)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
S. Matsumoto: "Involvement of multiple human cytochrome P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine"Br. J. Clin. Pharmacol.. 51. 133-142 (2001)
S. Matsumoto:“多种人细胞色素 P450 在阿司咪唑肝微粒体代谢中的参与以及与特非那定的比较”Br。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
M. Miyata: "Suppression of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induce d DNA damage in rat colon after grapefruit juice intake"Cancer Lette.. (in press).
M. Miyata:“摄入葡萄柚汁后大鼠结肠中 2-氨基-1-甲基-6-苯基咪唑[4,5-b]吡啶诱导的 d DNA 损伤的抑制”Cancer Letter..(出版中)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
S.Matsumoto: "Involvement of multiple human cytochrome P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine"Br. J. Clin. Pharmacol.. 51. 133-142 (2001)
S.Matsumoto:“多种人细胞色素 P450 参与阿司咪唑的肝微粒体代谢以及与特非那定的比较”Br。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
M.Miyata: "Suppression of 2-amino-1-methyl-6-phenylimedazo[4,5-b]pyridine-induced DNA damage in rat colon after grapefruit juice intake"Cancer Lette.. (in press).
M.Miyata:“摄入葡萄柚汁后抑制 2-氨基-1-甲基-6-苯基咪唑并[4,5-b]吡啶诱导的大鼠结肠 DNA 损伤”Cancer Lette..(出版中)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
W.Tassaneeyakul: "Inhibition selectivity of grapefruit juice components on human cytochromes P450."Arch.Biochem.Biophys.. 378. 356-363 (2000)
W.Tassaneeyakul:“葡萄柚汁成分对人细胞色素 P450 的抑制选择性。”Arch.Biochem.Biophys.. 378. 356-363 (2000)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YAMAZOE Yasushi其他文献

YAMAZOE Yasushi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YAMAZOE Yasushi', 18)}}的其他基金

CYP3A4 induction-associated dyslipidemia : a new risk factor for lifestyle disease
CYP3A4诱导相关的血脂异常:生活方式病的新危险因素
  • 批准号:
    22659028
  • 财政年份:
    2010
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Regulation of hepatic lipid metabolism through ileal bile acid-FGF signaling
通过回肠胆汁酸-FGF信号调节肝脏脂质代谢
  • 批准号:
    21390039
  • 财政年份:
    2009
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mechanisms for delayed organ toxicity induced by drug and prediction system using comprehensive analysis
药物迟发性器官毒性机制及综合分析预测系统
  • 批准号:
    19390037
  • 财政年份:
    2007
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mechanism for human-specific hepatotoxicity and development of prediction system
人类特异性肝毒性机制及预测系统开发
  • 批准号:
    17390039
  • 财政年份:
    2005
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Bile acids, key compounds for the mechanistic analyses of hepatotoxicity, and nuclear receptor interaction
胆汁酸,肝毒性机制分析和核受体相互作用的关键化合物
  • 批准号:
    15390043
  • 财政年份:
    2003
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Human characteristic mechanism of enzyme induction and the prediction
人体特有的酶诱导机制及预测
  • 批准号:
    13470510
  • 财政年份:
    2001
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Role of intestinal oxidative metabolism on first pass effect
肠道氧化代谢对首过效应的作用
  • 批准号:
    09470496
  • 财政年份:
    1997
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of as table expression system for human drug metabolizing enzymes
人药物代谢酶as表表达系统的开发
  • 批准号:
    07557149
  • 财政年份:
    1995
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Analysis of mechanism of neonatal imprinting of drug-metabolizing enzymes of rat liver
大鼠肝脏药物代谢酶新生期印记机制分析
  • 批准号:
    60480130
  • 财政年份:
    1985
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (B)

相似海外基金

PHARMACOKINETIC AND PHARMACODYNAMIC TRIALS FOR MEDICATION DEVELOPMENT IN SUD. TO1 PHASE 1 COCAINE DRUG INTERACTION SEPTEMBER 25, 2023 TO MARCH 24, 2025. N01DA-23-893
SUD 药物开发的药代动力学和药效动力学试验。
  • 批准号:
    10937538
  • 财政年份:
    2023
  • 资助金额:
    $ 8.45万
  • 项目类别:
PHASE I COCAINE DRUG INTERACTION STUDY. TO6. NIDA PHARMACOKINETIC ANALYSIS RESOURCE CENTER. 08/10/2023 - 02/09/2025. NIDA REF. NO. N01DA-19-8947.
第一阶段可卡因药物相互作用研究。
  • 批准号:
    10937276
  • 财政年份:
    2023
  • 资助金额:
    $ 8.45万
  • 项目类别:
Structure/Function Drug Interaction Studies on Voltage-Gated Sodium Channels
电压门控钠通道的结构/功能药物相互作用研究
  • 批准号:
    BB/V018035/1
  • 财政年份:
    2022
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Research Grant
Investigation of the Immune-Mediated Drug-Drug Interaction Potential of Immune Checkpoint Inhibitors
免疫检查点抑制剂免疫介导的药物相互作用潜力的研究
  • 批准号:
    10677895
  • 财政年份:
    2022
  • 资助金额:
    $ 8.45万
  • 项目类别:
Genomic and drug-drug interaction mechanisms of interindividual variability in drug disposition
药物处置个体差异的基因组和药物相互作用机制
  • 批准号:
    10406564
  • 财政年份:
    2022
  • 资助金额:
    $ 8.45万
  • 项目类别:
Investigation of the Immune-Mediated Drug-Drug Interaction Potential of Immune Checkpoint Inhibitors
免疫检查点抑制剂免疫介导的药物相互作用潜力的研究
  • 批准号:
    10506483
  • 财政年份:
    2022
  • 资助金额:
    $ 8.45万
  • 项目类别:
Genomic and drug-drug interaction mechanisms of interindividual variability in drug disposition
药物处置个体差异的基因组和药物相互作用机制
  • 批准号:
    10598140
  • 财政年份:
    2022
  • 资助金额:
    $ 8.45万
  • 项目类别:
Identification and evaluation of novel biomarkers by metabolome analysis for drug interaction on renal drug transporters
通过代谢组分析鉴定和评估肾脏药物转运蛋白药物相互作用的新型生物标志物
  • 批准号:
    22K15311
  • 财政年份:
    2022
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Unravelling the mechanism of acai BDS-anticancer drug interaction: A preliminary approach
揭示巴西莓 BDS 与抗癌药物相互作用的机制:初步方法
  • 批准号:
    10291596
  • 财政年份:
    2021
  • 资助金额:
    $ 8.45万
  • 项目类别:
DDI-on-a-chip: an optimized liver microphysiological system and microenvironment for complex drug-drug interaction studies
DDI-on-a-chip:用于复杂药物相互作用研究的优化肝脏微生理系统和微环境
  • 批准号:
    10324897
  • 财政年份:
    2021
  • 资助金额:
    $ 8.45万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了